On July 3, uniQure N.V. declined 8.11% in regular trading, trading at $41.4/share with turnover of approximately $60.42 million. The stock has now fallen well below the $45.50 offering price from its recently completed public offering.

The decline is primarily attributed to ongoing dilution pressure from the company's public stock offering, which closed on June 26. The offering was initially planned at $150 million but was progressively upsized — first to $225 million and ultimately to approximately $259 million — with nearly 5.69 million common shares sold at $45.50 each, including full exercise of the underwriters' overallotment option of 741,758 shares. Proceeds are intended to advance AMT-130, its Huntington's disease gene therapy candidate, and support other pipeline programs.

The stock had previously rallied significantly after the FDA indicated it would accept a Biologics License Application based on three-year data, with RBC Capital Markets raising its price target to $65 and estimating a 75% probability of approval. The current pullback appears to reflect profit-taking and the absorption of substantial share dilution following the offering's completion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)